Sio Capital Management LLC Purchases Shares of 121,178 Artivion, Inc. (NYSE:AORT)

Sio Capital Management LLC acquired a new stake in Artivion, Inc. (NYSE:AORT) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 121,178 shares of the company’s stock, valued at approximately $3,226,000. Artivion comprises approximately 1.3% of Sio Capital Management LLC’s investment portfolio, making the stock its 20th largest position.

Other large investors also recently modified their holdings of the company. nVerses Capital LLC bought a new position in shares of Artivion during the second quarter worth approximately $28,000. RiverPark Advisors LLC bought a new stake in shares of Artivion in the second quarter valued at about $55,000. RW Investment Management LLC acquired a new position in shares of Artivion in the second quarter valued at about $219,000. Intech Investment Management LLC acquired a new stake in Artivion in the 2nd quarter worth about $253,000. Finally, Tidal Investments LLC acquired a new position in shares of Artivion during the 1st quarter worth approximately $257,000. 86.37% of the stock is owned by institutional investors.

Artivion Price Performance

AORT stock opened at $29.05 on Friday. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $30.00. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The company has a 50 day simple moving average of $26.91 and a 200 day simple moving average of $25.75.

Insider Activity

In related news, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. This trade represents a 8.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of analyst reports. JMP Securities started coverage on shares of Artivion in a research report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 price target for the company. Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Oppenheimer increased their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $31.00.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.